Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666757 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 750
- Enrollment target
NCT00666757: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00666757 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 750 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666757, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 750 participants
- Enrollment target
Study Summary
The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.
Primary Outcome
Visitwise probability of participants per treatment meeting remission criteria (QIDS-SR total score \[TS\]\</=5 at week 12 endpoint) were estimated using a pseudolikelihood-based mixed-models repeated measures analysis for a categorical outcome, model included fixed, categorical effects of treatment group (duloxetine vs. SSRIs), visit, treatment group-by-visit \& continuous, fixed covariate of baseline QIDS-SR TS, and random effect of participant. Primary analysis contrasted remission probabilit
Interventions
- DRUG sertraline
- DRUG duloxetine
- DRUG paroxetine
- DRUG fluoxetine
- DRUG citalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
What the finished NCT00666757 record still lists
NCT00666757 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 5 interventions - of which sertraline is the first listed.
NCT00666757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00666757 about?
NCT00666757 is a clinical study titled "A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression". The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.
What is the current status of trial NCT00666757?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 750 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00666757?
The interventions under investigation include: sertraline (DRUG), duloxetine (DRUG), paroxetine (DRUG), fluoxetine (DRUG), citalopram (DRUG).
Who is sponsoring clinical trial NCT00666757?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00666757's enrollment target sits among peer trials
750 108th of 2000 higher than 1,890 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia